JP2022542505A - 抗ｐｖｒｉｇ抗体製剤およびそれらの使用 - Google Patents

抗ｐｖｒｉｇ抗体製剤およびそれらの使用 Download PDF

Info

Publication number
JP2022542505A
JP2022542505A JP2022505499A JP2022505499A JP2022542505A JP 2022542505 A JP2022542505 A JP 2022542505A JP 2022505499 A JP2022505499 A JP 2022505499A JP 2022505499 A JP2022505499 A JP 2022505499A JP 2022542505 A JP2022542505 A JP 2022542505A
Authority
JP
Japan
Prior art keywords
pharmaceutical formulation
pvrig
cha
cancer
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022505499A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022542505A5 (https=
Inventor
ホワイト，マーク
アデオイ，アデボイ，ヘンリー
バックリー，マイケル
ルー，ジュン
ハンター，ジョン
ダヤグ，アナット コーヘン
Original Assignee
コンピュジェン リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by コンピュジェン リミテッド filed Critical コンピュジェン リミテッド
Publication of JP2022542505A publication Critical patent/JP2022542505A/ja
Publication of JP2022542505A5 publication Critical patent/JP2022542505A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
JP2022505499A 2019-07-29 2020-07-28 抗ｐｖｒｉｇ抗体製剤およびそれらの使用 Pending JP2022542505A (ja)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US201962880021P 2019-07-29 2019-07-29
US62/880,021 2019-07-29
US201962893051P 2019-08-28 2019-08-28
US62/893,051 2019-08-28
US201962930206P 2019-11-04 2019-11-04
US62/930,206 2019-11-04
US202062968660P 2020-01-31 2020-01-31
US62/968,660 2020-01-31
US202062985702P 2020-03-05 2020-03-05
US62/985,702 2020-03-05
US202063009367P 2020-04-13 2020-04-13
US63/009,367 2020-04-13
PCT/US2020/043921 WO2021021837A2 (en) 2019-07-29 2020-07-28 Anti-pvrig antibodies formulations and uses thereof

Publications (2)

Publication Number Publication Date
JP2022542505A true JP2022542505A (ja) 2022-10-04
JP2022542505A5 JP2022542505A5 (https=) 2023-08-29

Family

ID=72243187

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022505499A Pending JP2022542505A (ja) 2019-07-29 2020-07-28 抗ｐｖｒｉｇ抗体製剤およびそれらの使用

Country Status (11)

Country Link
US (1) US20220280643A1 (https=)
EP (1) EP4003417A2 (https=)
JP (1) JP2022542505A (https=)
KR (1) KR20220041881A (https=)
CN (1) CN114615993A (https=)
AU (1) AU2020323926A1 (https=)
BR (1) BR112022001575A2 (https=)
CA (1) CA3149093A1 (https=)
IL (1) IL290141A (https=)
MX (1) MX2022001146A (https=)
WO (1) WO2021021837A2 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL317989A (en) 2016-08-17 2025-02-01 Compugen Ltd Anti-TIGIT antibodies, anti-PVRIG antibodies and combinations thereof
TW202216778A (zh) 2020-07-15 2022-05-01 美商安進公司 Ｔｉｇｉｔ及ｃｄ１１２ｒ阻斷
WO2022069940A1 (en) * 2020-09-30 2022-04-07 Compugen Ltd. Combination therapy with anti-pvrig antibodies formulations, anti-tigit antibodies, and anti-pd-1 antibodies
WO2022171080A1 (zh) * 2021-02-09 2022-08-18 上海君实生物医药科技股份有限公司 抗cd112r抗体及其用途
EP4403574A4 (en) 2021-09-15 2025-10-29 Jiangsu Hengrui Pharmaceuticals Co Ltd PD-1-Specific Protein and Its Pharmaceutical Use
EP4403573A4 (en) * 2021-09-15 2024-12-25 Jiangsu Hengrui Pharmaceuticals Co., Ltd. PHARMACEUTICAL COMPOSITION CONTAINING BISPECIFIC ANTI-PVRIG/TIGIT ANTIBODY
WO2024027824A1 (zh) * 2022-08-05 2024-02-08 上海君实生物医药科技股份有限公司 抗cd112r抗体药物组合物及其用途
CN120112553A (zh) * 2022-08-10 2025-06-06 广州百济神州生物制药有限公司 抗pvrig抗体和使用方法
CN117957254A (zh) * 2022-08-31 2024-04-30 石药集团巨石生物制药有限公司 抗pvrig抗体及其应用
KR20250156744A (ko) 2023-03-15 2025-11-03 상하이 맙젠 바이오텍 리미티드 Pd-1/pvrig/tigit 결합 단백질을 함유하는 약학적 조성물 및 이의 의약적 용도
WO2024245388A1 (zh) * 2023-06-01 2024-12-05 信达生物制药(苏州)有限公司 抗pvrig抗体及其应用
TW202502812A (zh) * 2023-06-06 2025-01-16 大陸商上海藥明生物技術有限公司 抗pvrig抗體及其用途
CN120005023B (zh) * 2023-12-22 2025-12-26 华润生物医药有限公司 抗pvrig抗体及其用途

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013520476A (ja) * 2010-02-26 2013-06-06 ノヴォ ノルディスク アー／エス 安定な抗体含有組成物
JP2017515909A (ja) * 2014-05-16 2017-06-15 グラクソスミスクライン、インテレクチュアル、プロパティー、マネジメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｍａｎａｇｅｍｅｎｔ Ｌｉｍｉｔｅｄ 抗体処方物
WO2018033798A1 (en) * 2016-08-17 2018-02-22 Compugen Ltd. Anti-tigit antibodies, anti-pvrig antibodies and combinations thereof
WO2018116198A1 (en) * 2016-12-23 2018-06-28 Serum Institute Of India Private Limited Improved methods for enhancing antibody productivity in mammalian cell culture and minimizing aggregation during downstream, formulation processes and stable antibody formulations obtained thereof
WO2018220446A1 (en) * 2017-06-01 2018-12-06 Compugen Ltd. Triple combination antibody therapies
JP2019509311A (ja) * 2016-03-25 2019-04-04 ビステラ， インコーポレイテッド デングウイルスに対する抗体分子の製剤

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9714A (en) 1853-05-10 Machine fob making hook-headed spikes
US289A (en) 1837-07-19 Cooking-stove
DE3572982D1 (en) 1984-03-06 1989-10-19 Takeda Chemical Industries Ltd Chemically modified lymphokine and production thereof
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
WO1990006952A1 (fr) 1988-12-22 1990-06-28 Kirin-Amgen, Inc. Facteur de stimulation de colonies de granulocytes modifies chimiquement
CA2118508A1 (en) 1992-04-24 1993-11-11 Elizabeth S. Ward Recombinant production of immunoglobulin-like domains in prokaryotic cells
ES2156149T3 (es) 1992-12-04 2001-06-16 Medical Res Council Proteinas de union multivalente y multiespecificas, su fabricacion y su uso.
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
DK1071700T3 (da) 1998-04-20 2010-06-07 Glycart Biotechnology Ag Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet
IL127127A0 (en) 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
PL209392B1 (pl) 1999-01-15 2011-08-31 Genentech Inc Przeciwciało, komórka gospodarza, sposób wytwarzania przeciwciała oraz zastosowanie przeciwciała
CA2704600C (en) 1999-04-09 2016-10-25 Kyowa Kirin Co., Ltd. A method for producing antibodies with increased adcc activity
CA2463879C (en) 2001-10-25 2012-12-04 Genentech, Inc. Glycoprotein compositions
BR0309145A (pt) 2002-04-09 2005-02-01 Kyowa Hakko Kogyo Kk Células das quais o genoma é modificado
MXPA05010555A (es) * 2003-04-04 2006-03-09 Genentech Inc Formulaciones de proteina y anticuerpo de alta concentracion.
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
DK3653221T5 (da) * 2015-02-19 2024-08-26 Compugen Ltd Anti-pvrig-antistoffer og anvendelsesfremgangsmåder
US10550173B2 (en) * 2015-02-19 2020-02-04 Compugen, Ltd. PVRIG polypeptides and methods of treatment
JP2023500651A (ja) * 2019-11-04 2023-01-10 コンピュジェン リミテッド 抗ｐｖｒｉｇ抗体製剤および抗ｐｄ－１抗体による併用療法
WO2022069940A1 (en) * 2020-09-30 2022-04-07 Compugen Ltd. Combination therapy with anti-pvrig antibodies formulations, anti-tigit antibodies, and anti-pd-1 antibodies
WO2022165275A2 (en) * 2021-01-28 2022-08-04 Compugen Ltd. Combination therapy with anti-pvrig antibodies formulations and anti-pd-1-antibodies
WO2022165266A1 (en) * 2021-01-28 2022-08-04 Compugen Ltd. Anti-pvrig antibodies formulations and uses thereof
US12462008B2 (en) 2021-04-23 2025-11-04 Beijing Boe Technology Development Co., Ltd. Unlocking control method and device, electronic apparatus, and computer-readable storage medium
WO2023064958A1 (en) * 2021-10-15 2023-04-20 Compugen Ltd. Combination therapy with anti-pvrig antibodies formulations, anti-tigit antibodies, and anti-pd-1 antibodies
US20240103010A1 (en) * 2022-03-18 2024-03-28 Compugen Ltd. Pvrl2 and/or pvrig as biomarkers for treatment
TW202515608A (zh) * 2023-06-26 2025-04-16 以色列商坎布根有限公司 Ｉｌ—１８ｂｐ拮抗抗體及其於癌症治療之單一療法及組合療法的用途

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013520476A (ja) * 2010-02-26 2013-06-06 ノヴォ ノルディスク アー／エス 安定な抗体含有組成物
JP2017515909A (ja) * 2014-05-16 2017-06-15 グラクソスミスクライン、インテレクチュアル、プロパティー、マネジメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｍａｎａｇｅｍｅｎｔ Ｌｉｍｉｔｅｄ 抗体処方物
JP2019509311A (ja) * 2016-03-25 2019-04-04 ビステラ， インコーポレイテッド デングウイルスに対する抗体分子の製剤
WO2018033798A1 (en) * 2016-08-17 2018-02-22 Compugen Ltd. Anti-tigit antibodies, anti-pvrig antibodies and combinations thereof
WO2018116198A1 (en) * 2016-12-23 2018-06-28 Serum Institute Of India Private Limited Improved methods for enhancing antibody productivity in mammalian cell culture and minimizing aggregation during downstream, formulation processes and stable antibody formulations obtained thereof
WO2018220446A1 (en) * 2017-06-01 2018-12-06 Compugen Ltd. Triple combination antibody therapies

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
"Advances in liquid formulations of parenteral therapeutic proteins", BIOTECHNOLOGY ADVANCES, vol. 37, JPN6024023910, 2019, pages 107412, ISSN: 0005538988 *
"バイオ医薬品（抗体医薬品）の製剤・剤形検討 −利便性の向上と今後の展開−", 政策研ニュース, JPN6024023909, 2017, pages 8 - 13, ISSN: 0005538987 *

Also Published As

Publication number Publication date
IL290141A (en) 2022-03-01
BR112022001575A2 (pt) 2022-04-19
WO2021021837A3 (en) 2021-03-11
AU2020323926A1 (en) 2022-03-10
KR20220041881A (ko) 2022-04-01
US20220280643A1 (en) 2022-09-08
MX2022001146A (es) 2022-03-17
EP4003417A2 (en) 2022-06-01
CA3149093A1 (en) 2021-02-04
WO2021021837A2 (en) 2021-02-04
CN114615993A (zh) 2022-06-10

Similar Documents

Publication Publication Date Title
JP2022542505A (ja) 抗ｐｖｒｉｇ抗体製剤およびそれらの使用
JP2023500651A (ja) 抗ｐｖｒｉｇ抗体製剤および抗ｐｄ－１抗体による併用療法
JP7720785B2 (ja) 低ｐＨで結合するために特異性が増強されたイピリムマブバリアント
US10196445B1 (en) Ipilimumab variant with enhanced ADCC
US20230365680A1 (en) Combination therapy with anti-pvrig antibodies formulations, anti-tigit antibodies, and anti-pd-1 antibodies
US20250382364A1 (en) Anti-tigit and anti-pvrig in monotherapy and combination treatments
US20250339522A1 (en) Combination therapy with anti-pvrig antibodies formulations, anti-tigit antibodies, and anti-pd-1 antibodies
US20240076373A1 (en) Combination therapy with anti-pvrig antibodies formulations and anti-pd-1 antibodies
US20240082397A1 (en) Anti-pvrig antibodies formulations and uses thereof
US20260000760A1 (en) Triple combination cancer therapy with anti-pvrig antibodies, anti-tigit antibodies, and pembrolizumab
WO2024182443A2 (en) Triple combination therapy with anti-pvrig antibodies, anti-tigit antibodies, and pembrolizumab
EA052161B1 (ru) Составы, содержащие анти-pvrig антитела, и их применение
US20260035460A1 (en) Combination therapy with anti-pvrig antibodies formulations and anti-pd-1 antibodies
US20260041633A1 (en) Anti-tigit antibody formulation
CN118946582A (zh) 抗糖皮质激素诱导的tnfr相关（gitr）蛋白抗体及其用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230728

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230728

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230814

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240618

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240620

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240917

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241118

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20241118

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250228

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250528

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250729

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250828

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20251118

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260317